PL365779A1 - A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents

A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Info

Publication number
PL365779A1
PL365779A1 PL01365779A PL36577901A PL365779A1 PL 365779 A1 PL365779 A1 PL 365779A1 PL 01365779 A PL01365779 A PL 01365779A PL 36577901 A PL36577901 A PL 36577901A PL 365779 A1 PL365779 A1 PL 365779A1
Authority
PL
Poland
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
PL01365779A
Other languages
Polish (pl)
Inventor
Poelje Paul D. Van
Mark D. Erion
Toshihiko Fujiwara
Original Assignee
Metabasis Therapeutics, Inc.
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics, Inc., Sankyo Company, Limited filed Critical Metabasis Therapeutics, Inc.
Publication of PL365779A1 publication Critical patent/PL365779A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
PL01365779A 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes PL365779A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06

Publications (1)

Publication Number Publication Date
PL365779A1 true PL365779A1 (en) 2005-01-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365779A PL365779A1 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (en)
JP (1) JP2004508297A (en)
KR (1) KR100854851B1 (en)
CN (2) CN100396283C (en)
AU (2) AU7327101A (en)
BR (1) BR0112212A (en)
CA (1) CA2412142A1 (en)
CZ (1) CZ20035A3 (en)
HU (1) HUP0301830A3 (en)
IL (2) IL153513A0 (en)
MX (1) MXPA02012713A (en)
NO (1) NO20030034L (en)
NZ (1) NZ523227A (en)
PL (1) PL365779A1 (en)
RU (1) RU2328308C2 (en)
SK (1) SK62003A3 (en)
WO (1) WO2002003978A2 (en)
ZA (1) ZA200300044B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CZ20023018A3 (en) 2000-03-08 2003-01-15 Metabasis Therapeutics, Inc. Novel fructose-1,6-bisphosphatase inhibitors containing aryl group
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
JP4733922B2 (en) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド Correction of eating behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
JP2008510018A (en) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド Novel thiazole inhibitor of fructose-1,6-bisphosphatase
CN101119748A (en) * 2004-12-13 2008-02-06 第一三共株式会社 Pharmaceutical composition for treatment of diabetes
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (en) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Preparation produced by dry process
EP2394647A1 (en) 2006-11-02 2011-12-14 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
UY35065A (en) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION
CN104788350A (en) * 2014-01-22 2015-07-22 天津大学 Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization
CN106831437B (en) * 2016-02-03 2019-06-21 华中师范大学 Ester type compound and its preparation method and application containing nitroethenyl group
CN114907285B (en) * 2021-02-10 2023-09-22 华中师范大学 Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93164A0 (en) * 1989-01-24 1990-11-05 Gensia Pharma Purine nucleosides and their medical use
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
JP2001515482A (en) * 1997-03-07 2001-09-18 メタバシス・セラピューティクス・インコーポレイテッド Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU3087099A (en) * 1998-03-16 1999-10-11 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
EP1112275B9 (en) * 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
PT1143955E (en) * 1998-12-24 2005-11-30 Metabasis Therapeutics Inc COMBINATION OF FBPASE INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
ES2436610T3 (en) * 2000-01-21 2014-01-03 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
WO2002003978A2 (en) 2002-01-17
CA2412142A1 (en) 2002-01-17
JP2004508297A (en) 2004-03-18
ZA200300044B (en) 2004-05-06
KR100854851B1 (en) 2008-08-27
CN1599612A (en) 2005-03-23
CZ20035A3 (en) 2003-05-14
NZ523227A (en) 2005-04-29
MXPA02012713A (en) 2004-09-10
NO20030034D0 (en) 2003-01-03
RU2328308C2 (en) 2008-07-10
WO2002003978A3 (en) 2003-10-16
SK62003A3 (en) 2003-09-11
AU2001273271B2 (en) 2006-01-05
NO20030034L (en) 2003-03-05
AU7327101A (en) 2002-01-21
BR0112212A (en) 2003-12-30
HUP0301830A2 (en) 2003-11-28
IL153513A0 (en) 2003-07-06
KR20030031952A (en) 2003-04-23
IL153513A (en) 2014-07-31
EP1372660A2 (en) 2004-01-02
HUP0301830A3 (en) 2007-10-29
CN101301294A (en) 2008-11-12
CN100396283C (en) 2008-06-25

Similar Documents

Publication Publication Date Title
HUP0302950A3 (en) Synergistic herbicidal composition and a process for its use
IL153513A0 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB9900416D0 (en) Inhibitors
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
IL158195A0 (en) Thiohydantoins and use thereof for treating diabetes
PL373301A1 (en) Phosphodiesterase 4 inhibitors
GB0025782D0 (en) Use of inhibitors
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
GB2361223B (en) Climbing appliance for roping-up and roping-down operations
EP1337255A4 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
HK1042695A1 (en) Prothease inhibitors
EP1222913A4 (en) Depilatories and agents for external use
HUP0204106A3 (en) Calcilytic compounds and process for their use
AU2001264273A1 (en) Amide compounds and use thereof
AUPQ582400A0 (en) A method of treatment and agents for use therein
GB0114572D0 (en) A method for the treatment of textile surfaces and compositions for use therein
GB2389113B (en) B-secretase inhibitor
EP1364653A4 (en) Casoase 3 inhibitors
GB0202187D0 (en) "Inhibitors"
HUP0402141A3 (en) Herbicidal composition and process for its use
HUP0500955A3 (en) Cucurbitacin-containing insecticidal composition and a process for its use
AU2002357594A1 (en) Nitrogen-containing heterocyclic compounds and use thereof
GB0021193D0 (en) Inhibitors
GB0029733D0 (en) Inhibitors

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)